Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 02, 2015 4:36 PM ET

Healthcare Equipment and Supplies

Company Overview of Bayer HealthCare LLC

Company Overview

Bayer HealthCare LLC develops, manufactures, and markets healthcare and medical products. The company offers blood glucose monitoring systems, diabetes self-care software, and lancing devices; and YAZ, a low-dose oral contraceptive. It also provides diagnostic testing for urinalysis, DCA, immunology, blood gas, and hematology; molecular and clinical chemistry testing to assess and manage health in a myriad of disease states, including cardiovascular, kidney and infectious diseases, oncology, and virology; and Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms, including nausea, phonophobia, and photophobia. The company offers an...

100 Bayer Boulevard

PO Box 915

Whippany, NJ 07981-0915

United States

Founded in 2002

Phone:

862-404-3000

Fax:

862-404-3022

Key Executives for Bayer HealthCare LLC

President and General Manager of Animal Health Division
President and General Manager, Animal Health Division, North America
President of Consumer Care Division
Sr. Vice President, Global Head, Product Supply -Biotech and Site Head
Bayer HealthCare Representative U.S.A.
Compensation as of Fiscal Year 2015.

Bayer HealthCare LLC Key Developments

U.S. Food & Drug Administration Approves Bayer HealthCare's Finacea(R) (azelaic acid) Foam 15% for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea

Bayer HealthCare announced that the U.S. Food & Drug Administration (FDA) has approved Finacea® (azelaic acid) Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Papulopustular rosacea is a skin disease causing inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead. Finacea® Foam was developed as part of a research and development collaboration between Foamix Pharmaceuticals Ltd. and Bayer HealthCare, utilizing Foamix's proprietary foam technology platform. According to a license agreement between the two companies, Foamix is entitled to royalties and certain milestone payments upon commercialization of Finacea® Foam.

Bayer HealthCare and Johns Hopkins University Collaborate to Develop New Ophthalmic Therapies

Bayer HealthCare and The Johns Hopkins University in Baltimore have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The partners will jointly work on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases that affect many people worldwide, including age-related macular degeneration (AMD), diabetic macular edema (DME), geographic atrophy, Stargardt's disease, and retinal vein occlusion (RVO). The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases. Under the agreement, Bayer and the Wilmer Eye Institute of Johns Hopkins will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet medical need. Both parties will contribute personnel and infrastructure to address important scientific questions. Bayer will have an option for the exclusive use of the collaboration results. Financial terms of the agreement were not disclosed.

Acura Pharmaceuticals, Inc. and Bayer Healthcare LLC Enter into License and Development Agreement

On June 15, 2015, Acura Pharmaceuticals Inc. and Bayer Healthcare LLC entered into a license and development agreement made as of June 5, 2015 to: (i) provide Bayer with a worldwide license to Acura’s Impede® technology for use in an undisclosed methamphetamine resistant pseudoephedrine-containing product and (ii) jointly develop the Product utilizing Impede® technology for the U.S. market. The agreement also grants Bayer first right to negotiate a license to the Impede® technology for certain other products. The term of the agreement with respect to each country expires when royalties are no longer payable with respect to such country. After expiration of the term Bayer retains a license to sell the product on a royalty free basis. Either party may terminate the agreement in its entirety if the other party materially breaches the agreement, subject to an applicable cure period, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. Bayer may terminate the agreement immediately prior to completion of development obligations or at any time upon six months prior written notice thereafter. The company may terminate the agreement with respect to the U.S. if Bayer ceases or suspends development or commercialization of the product for a certain period of time.

Similar Private Companies By Industry

Company Name Region
Pathfinder Therapeutics, Inc. United States
Pattison Cole LLC United States
Electrochemical Research Corporation United States
ROHO, Inc. United States
Sanders Medical Products, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bayer HealthCare LLC, please visit www.bayer.us. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.